4X68
Crystal Structure of OP0595 complexed with AmpC
4X68 の概要
| エントリーDOI | 10.2210/pdb4x68/pdb |
| 関連するPDBエントリー | 4X69 |
| 分子名称 | Beta-lactamase, (2S,5R)-N-(2-aminoethoxy)-1-formyl-5-[(sulfooxy)amino]piperidine-2-carboxamide, NICKEL (II) ION, ... (4 entities in total) |
| 機能のキーワード | hydrolase, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor |
| 由来する生物種 | Pseudomonas aeruginosa |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 79294.74 |
| 構造登録者 | |
| 主引用文献 | Morinaka, A.,Tsutsumi, Y.,Yamada, M.,Suzuki, K.,Watanabe, T.,Abe, T.,Furuuchi, T.,Inamura, S.,Sakamaki, Y.,Mitsuhashi, N.,Ida, T.,Livermore, D.M. OP0595, a new diazabicyclooctane: mode of action as a serine beta-lactamase inhibitor, antibiotic and beta-lactam 'enhancer' J.Antimicrob.Chemother., 70:2779-2786, 2015 Cited by PubMed Abstract: The production of a growing diversity of β-lactamases by Gram-negative bacteria challenges antimicrobial chemotherapy. OP0595, discovered separately by each of Meiji Seika Pharma and Fedora Pharmaceuticals, is a new diazabicyclooctane serine β-lactamase inhibitor that also acts as an antibiotic and as a β-lactamase-independent β-lactam 'enhancer'. PubMed: 26089439DOI: 10.1093/jac/dkv166 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.68 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






